NCT03835013View on ClinicalTrials.gov

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

November 1, 2021

Study Completion Date

November 1, 2021

Conditions
Cardiovascular Diseases
Interventions
DRUG

Saline 0.9%

Intravenous infusion of 0.9% saline

DRUG

Glucagon (25ng/kg/min)

Intravenous infusion of glucagon 25ng/kg/min

DRUG

Glucagon (50ng/kg/min)

Intravenous infusion of glucagon 50ng/kg/min

DRUG

Exenatide

Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes

Trial Locations (1)

CB2 0QQ

Addenbrooke's Hospital, Cambridge

All Listed Sponsors
lead

Cambridge University Hospitals NHS Foundation Trust

OTHER

NCT03835013 - Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter